235 related articles for article (PubMed ID: 28965354)
1. Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis.
Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
Int J Urol; 2018 Jan; 25(1):54-60. PubMed ID: 28965354
[TBL] [Abstract][Full Text] [Related]
2. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
Nishiura Y; Nakamura T; Fukushima N; Nakamura H; Ida H; Aramaki T; Eguchi K
Antivir Ther; 2009; 14(4):533-42. PubMed ID: 19578238
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial.
Nakamura T; Matsuo T; Fukuda T; Yamato S; Yamaguchi K; Kinoshita I; Matsuzaki T; Nishiura Y; Nagasato K; Narita-Masuda T; Nakamura H; Satoh K; Sasaki H; Sakai H; Kawakami A
BMC Med; 2013 Aug; 11():182. PubMed ID: 23945290
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
Low Urin Tract Symptoms; 2019 Apr; 11(2):O65-O70. PubMed ID: 29473309
[TBL] [Abstract][Full Text] [Related]
5. Retrospective clinic and urodynamic study in the neurogenic bladder dysfunction caused by human T cell lymphotrophic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Troisgros O; Barnay JL; Darbon-Naghibzadeh F; Olive P; René-Corail P
Neurourol Urodyn; 2017 Feb; 36(2):449-452. PubMed ID: 26756420
[TBL] [Abstract][Full Text] [Related]
6. Voiding dysfunction in patients with human T-lymphotropic-virus-type-1-associated myelopathy.
Komine S; Yoshida H; Fujiyama C; Masaki Z
Urol Int; 1991; 47 Suppl 1():67-8. PubMed ID: 1949381
[TBL] [Abstract][Full Text] [Related]
7. Voiding dysfunction: patients with human T-lymphotropic-virus-type-1-associated myelopathy.
Yamashita H; Kumazawa J
Urol Int; 1991; 47 Suppl 1():69-71. PubMed ID: 1949382
[TBL] [Abstract][Full Text] [Related]
8. Urinary dysfunction in tropical spastic paraparesis: preliminary urodynamic survey.
Walton GW; Kaplan SA
J Urol; 1993 Sep; 150(3):930-2. PubMed ID: 8345613
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Kira J
BMC Med; 2013 Aug; 11():183. PubMed ID: 23945332
[TBL] [Abstract][Full Text] [Related]
10. [Studies on neurogenic bladder due to human T-lymphotropic virus type-I associated myelopathy (HAM)].
Imamura A
Nihon Hinyokika Gakkai Zasshi; 1994 Jul; 85(7):1106-15. PubMed ID: 8078228
[TBL] [Abstract][Full Text] [Related]
11. [Urinary disturbance due to HTLV-1 associated myelopathy].
Sakiyama H; Nishi K; Kikukawa H; Ueda S
Nihon Hinyokika Gakkai Zasshi; 1992 Dec; 83(12):2058-61. PubMed ID: 1474715
[TBL] [Abstract][Full Text] [Related]
12. Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
Matarazzo MG; Caruso S; Giunta G; Valenti G; Sarpietro G; Cianci A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():75-79. PubMed ID: 29367168
[TBL] [Abstract][Full Text] [Related]
13. Overactive bladder changes with time: a 5-year longitudinal followup of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels.
Chuang FC; Liu HT; Wang LY; Kuo HC
J Urol; 2014 Aug; 192(2):458-63. PubMed ID: 24594404
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
15. Micturitional disturbance in human T-lymphotropic virus type-1-associated myelopathy.
Hattori T; Sakakibara R; Yamanishi T; Yasuda K; Hirayama K
J Spinal Disord; 1994 Jun; 7(3):255-8. PubMed ID: 7919650
[TBL] [Abstract][Full Text] [Related]
16. Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.
Matsuo T; Nakamura T; Sato K; Miyata Y; Sakai H
IJU Case Rep; 2021 Jul; 4(4):251-254. PubMed ID: 34258542
[TBL] [Abstract][Full Text] [Related]
17. Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis.
Yamakawa N; Yagishita N; Matsuo T; Yamauchi J; Ueno T; Inoue E; Takata A; Nagasaka M; Araya N; Hasegawa D; Coler-Reilly A; Tsutsumi S; Sato T; Araujo A; Casseb J; Gotuzzo E; Jacobson S; Martin F; Puccioni-Sohler M; Taylor GP; Yamano Y;
Orphanet J Rare Dis; 2020 Jul; 15(1):175. PubMed ID: 32620176
[TBL] [Abstract][Full Text] [Related]
18. [NERVE GROWTH FACTOR IN THE URINE OF PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY AND OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
Krivoborodov GG; Kolesanova EF; Tur EI; Efremov NS
Urologiia; 2015; (3):19-22. PubMed ID: 26390554
[TBL] [Abstract][Full Text] [Related]
19. Clinical manifestation of human T-cell lymphotropic virus type-I-associated myelopathy and vesicopathy.
Imamura A; Kitagawa T; Ohi Y; Osame M
Urol Int; 1991; 46(2):149-53. PubMed ID: 2053222
[TBL] [Abstract][Full Text] [Related]
20. Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals.
Castro NM; Freitas DM; Rodrigues W; Muniz A; Oliveira P; Carvalho EM
Int Braz J Urol; 2007; 33(2):238-44; discussion 244-5. PubMed ID: 17488545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
